<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://m2.mtmt.hu/xsl/gui3.xsl" ?>
<myciteResult>
  <serverUrl>https://m2.mtmt.hu/</serverUrl>
  <labelLang>hun</labelLang>
  <responseDate>2026-09-21 21:47</responseDate>
  <content>
    <publication>
      <otype>JournalArticle</otype>
      <mtid>33770031</mtid>
      <status>VALIDATED</status>
      <published>true</published>
      <comment>Cited By :12            
            Export Date: 10 December 2024            
            Correspondence Address: Fekete, A.; Pediatric Center, Hungary; email: fekete.andrea@med.semmelweis-univ.hu</comment>
      <unhandledTickets>0</unhandledTickets>
      <deleted>false</deleted>
      <lastRefresh>2026-08-24T07:04:20.255+0000</lastRefresh>
      <lastModified>2025-11-18T09:25:55.628+0000</lastModified>
      <created>2023-04-25T06:52:09.561+0000</created>
      <creator>
        <snippet>true</snippet>
        <mtid>10045296</mtid>
        <familyName>Cseh</familyName>
        <givenName>Éva</givenName>
        <link>/api/admin/10045296</link>
        <otype>Admin</otype>
        <label>Cseh Éva (SE_AOK_Adm5_1GyermekgyCsehÉva, admin)</label>
        <published>true</published>
        <oldId>10045296</oldId>
      </creator>
      <lastDuplumSearch>2026-07-06T06:31:33.656+0000</lastDuplumSearch>
      <validated>2024-12-06T18:04:16.334+0000</validated>
      <validator>
        <snippet>true</snippet>
        <mtid>10039043</mtid>
        <familyName>Milánkovics</familyName>
        <givenName>Róbert</givenName>
        <link>/api/admin/10039043</link>
        <otype>Admin</otype>
        <label>Milánkovics Róbert (PTE ÁOK admin 4)</label>
        <published>true</published>
        <oldId>10039043</oldId>
      </validator>
      <core>true</core>
      <publicationPending>false</publicationPending>
      <type>
        <snippet>true</snippet>
        <mtid>24</mtid>
        <code>24</code>
        <link>/api/publicationtype/24</link>
        <otype>PublicationType</otype>
        <label>Folyóiratcikk</label>
        <listPosition>1</listPosition>
        <published>true</published>
        <oldId>24</oldId>
        <otypeName>JournalArticle</otypeName>
      </type>
      <subType>
        <snippet>true</snippet>
        <mtid>1134514</mtid>
        <nameEng>Survey paper</nameEng>
        <docType>
          <snippet>true</snippet>
          <mtid>24</mtid>
          <code>24</code>
          <link>/api/publicationtype/24</link>
          <otype>PublicationType</otype>
          <label>Folyóiratcikk</label>
          <listPosition>1</listPosition>
          <published>true</published>
          <oldId>24</oldId>
          <otypeName>JournalArticle</otypeName>
        </docType>
        <link>/api/subtype/1134514</link>
        <name>Összefoglaló cikk</name>
        <otype>SubType</otype>
        <label>Összefoglaló cikk (Folyóiratcikk)</label>
        <listPosition>102</listPosition>
        <published>true</published>
        <oldId>1134514</oldId>
      </subType>
      <category>
        <snippet>true</snippet>
        <mtid>1</mtid>
        <link>/api/category/1</link>
        <otype>Category</otype>
        <label>Tudományos</label>
        <published>true</published>
        <oldId>1</oldId>
      </category>
      <firstAuthor>Balogh, Dora Bianka</firstAuthor>
      <title>An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis</title>
      <journal>
        <snippet>true</snippet>
        <sciIndexed>true</sciIndexed>
        <link>/api/journal/10003252</link>
        <reviewType>REVIEWED</reviewType>
        <label>INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067</label>
        <published>true</published>
        <hungarian>false</hungarian>
        <oldId>10003252</oldId>
        <noIF>false</noIF>
        <mtid>10003252</mtid>
        <scopusIndexed>true</scopusIndexed>
        <pIssn>1661-6596</pIssn>
        <eIssn>1422-0067</eIssn>
        <otype>Journal</otype>
        <lang>FOREIGN</lang>
      </journal>
      <volume>24</volume>
      <issue>9</issue>
      <internalId>7789</internalId>
      <firstPageOrInternalIdForSort>7789</firstPageOrInternalIdForSort>
      <pageLength>18</pageLength>
      <publishedYear>2023</publishedYear>
      <abstractText>Metabolic diseases, particularly diabetes mellitus (DM), are significant global public health concerns. Despite the widespread use of standard-of-care therapies, cardiovascular disease (CVD) remains the leading cause of death among diabetic patients. Early and evidence-based interventions to reduce CVD are urgently needed. Large clinical trials have recently shown that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) ameliorate adverse cardiorenal outcomes in patients with type 2 DM. These quite unexpected positive results represent a paradigm shift in type 2 DM management, from the sole importance of glycemic control to the simultaneous improvement of cardiovascular outcomes. Moreover, SGLT2i is also found to be cardio- and nephroprotective in non-diabetic patients. Several mechanisms, which may be potentially independent or at least separate from the reduction in blood glucose levels, have already been identified behind the beneficial effect of these drugs. However, there is still much to be understood regarding the exact pathomechanisms. This review provides an overview of the current literature and sheds light on the modes of action of novel antidiabetic drugs, focusing on inflammation, oxidative stress, and fibrosis.</abstractText>
      <fundings>
        <funding>
          <otype>Funding</otype>
          <mtid>2027207</mtid>
          <link>/api/funding/2027207</link>
          <label>(UNKP-22-4-II-SE-2)</label>
          <published>false</published>
          <snippet>true</snippet>
        </funding>
        <funding>
          <otype>Funding</otype>
          <mtid>2027208</mtid>
          <link>/api/funding/2027208</link>
          <label>(TKP2021-EGA-24)</label>
          <published>false</published>
          <snippet>true</snippet>
        </funding>
        <funding>
          <otype>Funding</otype>
          <mtid>2027209</mtid>
          <link>/api/funding/2027209</link>
          <label>(TKP2021-EGA-24)</label>
          <published>false</published>
          <snippet>true</snippet>
        </funding>
      </fundings>
      <digital>true</digital>
      <printed/>
      <sourceYear>2023</sourceYear>
      <foreignEdition>true</foreignEdition>
      <foreignLanguage>true</foreignLanguage>
      <fullPublication>true</fullPublication>
      <conferencePublication>false</conferencePublication>
      <nationalOrigin>true</nationalOrigin>
      <missingAuthor>false</missingAuthor>
      <oaType>GOLD</oaType>
      <oaCheckDate>2026-08-24</oaCheckDate>
      <oaFree>true</oaFree>
      <oaLink>https://doi.org/10.3390/ijms24097789</oaLink>
      <citationCount>47</citationCount>
      <citationCountUnpublished>0</citationCountUnpublished>
      <citationCountWoOther>42</citationCountWoOther>
      <independentCitCountWoOther>42</independentCitCountWoOther>
      <nationalOriginCitationCount>0</nationalOriginCitationCount>
      <foreignEditionCitationCount>42</foreignEditionCitationCount>
      <doiCitationCount>42</doiCitationCount>
      <wosCitationCount>36</wosCitationCount>
      <scopusCitationCount>37</scopusCitationCount>
      <wosScopusCitationCount>40</wosScopusCitationCount>
      <wosScopusCitationCountWoOther>40</wosScopusCitationCountWoOther>
      <wosScopusIndependentCitationCount>40</wosScopusIndependentCitationCount>
      <wosScopusIndependentCitationCountWoOther>40</wosScopusIndependentCitationCountWoOther>
      <independentCitationCount>47</independentCitationCount>
      <selfCitationCount>0</selfCitationCount>
      <unhandledCitationCount>0</unhandledCitationCount>
      <citingPubCount>47</citingPubCount>
      <independentCitingPubCount>47</independentCitingPubCount>
      <citingPubCountWoOther>42</citingPubCountWoOther>
      <independentCitingPubCountWoOther>42</independentCitingPubCountWoOther>
      <unhandledCitingPubCount>0</unhandledCitingPubCount>
      <citedPubCount>8</citedPubCount>
      <citedCount>8</citedCount>
      <pubStats>
        <types>
          <type>Folyóiratcikk</type>
          <typeEng>Journal Article</typeEng>
          <code>24</code>
          <count>41</count>
        </types>
        <types>
          <type>Könyvrészlet</type>
          <typeEng>Chapter in Book</typeEng>
          <code>25</code>
          <count>1</count>
        </types>
        <types>
          <type>Könyv</type>
          <typeEng>Book</typeEng>
          <code>23</code>
          <count>0</count>
        </types>
        <types>
          <type>Egyéb konferenciaközlemény</type>
          <typeEng>Conference paper</typeEng>
          <code>31</code>
          <count>0</count>
        </types>
        <types>
          <type>Egyéb konferenciakötet</type>
          <typeEng>Conference proceedings</typeEng>
          <code>32</code>
          <count>0</count>
        </types>
        <types>
          <type>Oltalmi formák</type>
          <typeEng>Protection forms</typeEng>
          <code>26</code>
          <count>0</count>
        </types>
        <types>
          <type>Disszertáció</type>
          <typeEng>Thesis</typeEng>
          <code>28</code>
          <count>5</count>
        </types>
        <types>
          <type>Egyéb</type>
          <typeEng>Miscellaneous</typeEng>
          <code>29</code>
          <count>0</count>
        </types>
        <types>
          <type>Alkotás</type>
          <typeEng>Achievement</typeEng>
          <code>22</code>
          <count>0</count>
        </types>
        <types>
          <type>Kutatási adat</type>
          <typeEng>Research data</typeEng>
          <code>33</code>
          <count>0</count>
        </types>
        <citationTypes>
          <type>Folyóiratcikk</type>
          <typeEng>Journal Article</typeEng>
          <code>24</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Könyvrészlet</type>
          <typeEng>Chapter in Book</typeEng>
          <code>25</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Könyv</type>
          <typeEng>Book</typeEng>
          <code>23</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Egyéb konferenciaközlemény</type>
          <typeEng>Conference paper</typeEng>
          <code>31</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Egyéb konferenciakötet</type>
          <typeEng>Conference proceedings</typeEng>
          <code>32</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Oltalmi formák</type>
          <typeEng>Protection forms</typeEng>
          <code>26</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Disszertáció</type>
          <typeEng>Thesis</typeEng>
          <code>28</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Egyéb</type>
          <typeEng>Miscellaneous</typeEng>
          <code>29</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Alkotás</type>
          <typeEng>Achievement</typeEng>
          <code>22</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <citationTypes>
          <type>Kutatási adat</type>
          <typeEng>Research data</typeEng>
          <code>33</code>
          <countUnknown>0</countUnknown>
          <countIndependent>0</countIndependent>
          <countSelfCitation>0</countSelfCitation>
        </citationTypes>
        <years>
          <year>2023</year>
          <publicationCount>0</publicationCount>
          <citationCount>2</citationCount>
          <independentCitationCount>2</independentCitationCount>
          <citingPubCount>2</citingPubCount>
          <independentCitingPubCount>2</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
        <years>
          <year>2024</year>
          <publicationCount>0</publicationCount>
          <citationCount>10</citationCount>
          <independentCitationCount>10</independentCitationCount>
          <citingPubCount>10</citingPubCount>
          <independentCitingPubCount>10</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
        <years>
          <year>2025</year>
          <publicationCount>0</publicationCount>
          <citationCount>23</citationCount>
          <independentCitationCount>23</independentCitationCount>
          <citingPubCount>23</citingPubCount>
          <independentCitingPubCount>23</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
        <years>
          <year>2026</year>
          <publicationCount>0</publicationCount>
          <citationCount>11</citationCount>
          <independentCitationCount>11</independentCitationCount>
          <citingPubCount>11</citingPubCount>
          <independentCitingPubCount>11</independentCitingPubCount>
          <oaStats/>
          <oaStats2/>
        </years>
      </pubStats>
      <ratingsForSort>D1</ratingsForSort>
      <hasCitationDuplums>false</hasCitationDuplums>
      <inSelectedPubs>10020375,10052792</inSelectedPubs>
      <importDuplum>false</importDuplum>
      <importOverwritten>false</importOverwritten>
      <importSkipped>false</importSkipped>
      <userChangeableUntil>2023-05-30T08:36:34.592+0000</userChangeableUntil>
      <directInstitutesForSort>Gyermekgyógyászati Klinika (SE / AOK / K); MTA-SE Lendület Diabétesz Kutatócsoport (SE / AOK / K / GYGYK); Sebészeti, Transzplantációs és Gasztroenterológ... (SE / AOK / K)</directInstitutesForSort>
      <ownerAuthorCount>3</ownerAuthorCount>
      <ownerInstituteCount>17</ownerInstituteCount>
      <directInstituteCount>3</directInstituteCount>
      <authorCount>3</authorCount>
      <contributorCount>0</contributorCount>
      <hasQualityFactor>true</hasQualityFactor>
      <languages>
        <language>
          <otype>Language</otype>
          <mtid>10002</mtid>
          <link>/api/language/10002</link>
          <label>Angol</label>
          <name>Angol</name>
          <nameEng>English</nameEng>
          <published>true</published>
          <oldId>2</oldId>
          <snippet>true</snippet>
        </language>
      </languages>
      <authorships>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>107454092</mtid>
          <link>/api/authorship/107454092</link>
          <label>Balogh, Dora Bianka [Balogh, Dóra Bianka (Molekuláris bioló...), szerző] MTA-SE Lendület Diabétesz Kutatócsoport (SE / AOK / K / GYGYK); Gyermekgyógyászati Klinika (SE / AOK / K)</label>
          <listPosition>1</listPosition>
          <share>0.333</share>
          <first>true</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <author>
            <otype>Author</otype>
            <mtid>10052792</mtid>
            <link>/api/author/10052792</link>
            <label>Balogh Dóra Bianka (Molekuláris biológia, Szülészet-nőgyógyászat)</label>
            <familyName>Balogh</familyName>
            <givenName>Dóra Bianka</givenName>
            <published>true</published>
            <oldId>10052792</oldId>
            <snippet>true</snippet>
          </author>
          <familyName>Balogh</familyName>
          <givenName>Dora Bianka</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>107454093</mtid>
          <link>/api/authorship/107454093</link>
          <label>Wagner, Laszlo Jozsef [Wágner, László József (Transzplantáció), szerző] Sebészeti, Transzplantációs és Gasztroenterológ... (SE / AOK / K)</label>
          <listPosition>2</listPosition>
          <share>0.333</share>
          <first>false</first>
          <last>false</last>
          <corresponding>false</corresponding>
          <author>
            <otype>Author</otype>
            <mtid>10020375</mtid>
            <link>/api/author/10020375</link>
            <label>Wágner László József (Transzplantáció)</label>
            <familyName>Wágner</familyName>
            <givenName>László József</givenName>
            <published>true</published>
            <oldId>10020375</oldId>
            <snippet>true</snippet>
          </author>
          <familyName>Wagner</familyName>
          <givenName>Laszlo Jozsef</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
        <authorship>
          <otype>PersonAuthorship</otype>
          <mtid>107454094</mtid>
          <link>/api/authorship/107454094</link>
          <label>Fekete, Andrea ✉ [Fekete, Andrea (nefrológia, gyerm...), szerző] MTA-SE Lendület Diabétesz Kutatócsoport (SE / AOK / K / GYGYK); Gyermekgyógyászati Klinika (SE / AOK / K)</label>
          <listPosition>3</listPosition>
          <share>0.333</share>
          <first>false</first>
          <last>true</last>
          <corresponding>true</corresponding>
          <author>
            <otype>Author</otype>
            <mtid>10011883</mtid>
            <link>/api/author/10011883</link>
            <label>Fekete Andrea (nefrológia, gyermekgyógyászat)</label>
            <familyName>Fekete</familyName>
            <givenName>Andrea</givenName>
            <published>true</published>
            <oldId>10011883</oldId>
            <snippet>true</snippet>
          </author>
          <familyName>Fekete</familyName>
          <givenName>Andrea</givenName>
          <authorTyped>true</authorTyped>
          <editorTyped>false</editorTyped>
          <otherTyped>false</otherTyped>
          <type>
            <otype>AuthorshipType</otype>
            <mtid>1</mtid>
            <link>/api/authorshiptype/1</link>
            <label>Szerző</label>
            <code>0</code>
            <published>true</published>
            <oldId>0</oldId>
            <snippet>true</snippet>
          </type>
          <published>false</published>
          <snippet>true</snippet>
        </authorship>
      </authorships>
      <identifiers>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>23421866</mtid>
          <link>/api/publicationidentifier/23421866</link>
          <label>DOI: 10.3390/ijms24097789</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>6</mtid>
            <link>/api/publicationsource/6</link>
            <label>DOI</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10001</mtid>
              <link>/api/publicationsourcetype/10001</link>
              <label>DOI</label>
              <mayHaveOa>true</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>DOI</name>
            <nameEng>DOI</nameEng>
            <linkPattern>https://doi.org/@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>6</oldId>
            <snippet>true</snippet>
          </source>
          <oaType>GOLD</oaType>
          <oaFree>true</oaFree>
          <validState>IDENTICAL</validState>
          <idValue>10.3390/ijms24097789</idValue>
          <realUrl>https://doi.org/10.3390/ijms24097789</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>23790771</mtid>
          <link>/api/publicationidentifier/23790771</link>
          <label>WoS: 000987420600001</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>1</mtid>
            <link>/api/publicationsource/1</link>
            <label>WoS</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>WoS</name>
            <nameEng>WoS</nameEng>
            <linkPattern>https://www.webofscience.com/wos/woscc/full-record/@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>1</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>000987420600001</idValue>
          <realUrl>https://www.webofscience.com/wos/woscc/full-record/000987420600001</realUrl>
          <published>false</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>23817191</mtid>
          <link>/api/publicationidentifier/23817191</link>
          <label>Scopus: 85159311837</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>3</mtid>
            <link>/api/publicationsource/3</link>
            <label>Scopus</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>Scopus</name>
            <nameEng>Scopus</nameEng>
            <linkPattern>http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-@@@</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>3</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>85159311837</idValue>
          <realUrl>http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85159311837</realUrl>
          <published>true</published>
          <snippet>true</snippet>
        </identifier>
        <identifier>
          <otype>PublicationIdentifier</otype>
          <mtid>23817204</mtid>
          <link>/api/publicationidentifier/23817204</link>
          <label>PubMed: 37175496</label>
          <source>
            <otype>PlainSource</otype>
            <mtid>17</mtid>
            <link>/api/publicationsource/17</link>
            <label>PubMed</label>
            <type>
              <otype>PublicationSourceType</otype>
              <mtid>10003</mtid>
              <link>/api/publicationsourcetype/10003</link>
              <label>Indexelő adatbázis</label>
              <mayHaveOa>false</mayHaveOa>
              <published>true</published>
              <snippet>true</snippet>
            </type>
            <name>PubMed</name>
            <nameEng>PubMed</nameEng>
            <linkPattern>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=@@@&amp;dopt=Abstract</linkPattern>
            <publiclyVisible>true</publiclyVisible>
            <published>true</published>
            <oldId>17</oldId>
            <snippet>true</snippet>
          </source>
          <validState>IDENTICAL</validState>
          <idValue>37175496</idValue>
          <realUrl>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=37175496&amp;dopt=Abstract</realUrl>
          <published>true</published>
          <snippet>true</snippet>
        </identifier>
      </identifiers>
      <ratings>
        <rating>
          <otype>SjrRating</otype>
          <mtid>11388415</mtid>
          <link>/api/sjrrating/11388415</link>
          <label>sjr:D1 (2023) Scopus - Inorganic Chemistry INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067</label>
          <listPos>7</listPos>
          <rankValue>0.1</rankValue>
          <type>journal</type>
          <ratingType>
            <otype>RatingType</otype>
            <mtid>10002</mtid>
            <link>/api/ratingtype/10002</link>
            <label>sjr</label>
            <code>sjr</code>
            <published>true</published>
            <snippet>true</snippet>
          </ratingType>
          <subject>
            <otype>ClassificationExternal</otype>
            <mtid>1604</mtid>
            <link>/api/classificationexternal/1604</link>
            <label>Scopus - Inorganic Chemistry</label>
            <published>true</published>
            <oldId>1604</oldId>
            <snippet>true</snippet>
          </subject>
          <ranking>D1</ranking>
          <calculation>DIRECT</calculation>
          <published>true</published>
          <snippet>true</snippet>
        </rating>
      </ratings>
      <references>
        <reference>
          <otype>Reference</otype>
          <mtid>40477443</mtid>
          <link>/api/reference/40477443</link>
          <label>1. Sun 2022: IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045., Diabetes Res. Clin. Pract., 183, p. 109119, DOI: 10.1016/j.diabres.2021.109119</label>
          <listPosition>1</listPosition>
          <doi>10.1016/j.diabres.2021.109119</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477444</mtid>
          <link>/api/reference/40477444</link>
          <label>2. Emerging Risk Factors Collaboration, Sarwar, N., Gao, P., Seshasai, S.R., Gobin, R., Kaptoge, S., Di Angelantonio, E., Ingelsson, E., Lawlor, D.A., and Selvin, E. (2010). Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet, 375, 2215–2222., DOI: 10.1016/S0140-6736(10)60484-9</label>
          <listPosition>2</listPosition>
          <doi>10.1016/S0140-6736(10)60484-9</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477445</mtid>
          <link>/api/reference/40477445</link>
          <label>3. Sun 2019: Type 2 Diabetes and Hypertension., Circ. Res., 124, p. 930, DOI: 10.1161/CIRCRESAHA.118.314487</label>
          <listPosition>3</listPosition>
          <doi>10.1161/CIRCRESAHA.118.314487</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477446</mtid>
          <link>/api/reference/40477446</link>
          <label>4. Cherney 2020: Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus., Am. J. Nephrol., 51, p. 74, DOI: 10.1159/000504558</label>
          <listPosition>4</listPosition>
          <doi>10.1159/000504558</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477447</mtid>
          <link>/api/reference/40477447</link>
          <label>5. Kaptoge 2011: Diabetes mellitus, fasting glucose, and risk of cause-specific death., N. Engl. J. Med., 364, p. 829, DOI: 10.1056/NEJMoa1008862</label>
          <listPosition>5</listPosition>
          <doi>10.1056/NEJMoa1008862</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477448</mtid>
          <link>/api/reference/40477448</link>
          <label>6. Shah 2015: Type 2 diabetes and incidence of cardiovascular diseases: A cohort study in 1.9 million people., Lancet Diabetes Endocrinol., 3, p. 105, DOI: 10.1016/S2213-8587(14)70219-0</label>
          <listPosition>6</listPosition>
          <doi>10.1016/S2213-8587(14)70219-0</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477449</mtid>
          <link>/api/reference/40477449</link>
          <label>7. Einarson 2018: Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017., Cardiovasc. Diabetol., 17, p. 83, DOI: 10.1186/s12933-018-0728-6</label>
          <listPosition>7</listPosition>
          <doi>10.1186/s12933-018-0728-6</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477450</mtid>
          <link>/api/reference/40477450</link>
          <label>8. Ma 2022: Cardiovascular disease in type 2 diabetes mellitus: Progress toward personalized management., Cardiovasc. Diabetol., 21, p. 74, DOI: 10.1186/s12933-022-01516-6</label>
          <listPosition>8</listPosition>
          <doi>10.1186/s12933-022-01516-6</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477451</mtid>
          <link>/api/reference/40477451</link>
          <label>9. Hiatt 2013: The cardiovascular safety of diabetes drugs—Insights from the rosiglitazone experience., N. Engl. J. Med., 369, p. 1285, DOI: 10.1056/NEJMp1309610</label>
          <listPosition>9</listPosition>
          <doi>10.1056/NEJMp1309610</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477452</mtid>
          <link>/api/reference/40477452</link>
          <label>10. US Food and Drug Administration (2020). Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry, US Food and Drug Administration.</label>
          <listPosition>10</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477453</mtid>
          <link>/api/reference/40477453</link>
          <label>11. Wright 2011: Biology of human sodium glucose transporters., Physiol. Rev., 91, p. 733, DOI: 10.1152/physrev.00055.2009</label>
          <listPosition>11</listPosition>
          <doi>10.1152/physrev.00055.2009</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477454</mtid>
          <link>/api/reference/40477454</link>
          <label>12. Capuano 2013: Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy—Focus on alogliptin., Drug Des. Devel. Ther., 7, p. 989</label>
          <listPosition>12</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477455</mtid>
          <link>/api/reference/40477455</link>
          <label>13. Meier 2012: GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus., Nat. Rev. Endocrinol., 8, p. 728, DOI: 10.1038/nrendo.2012.140</label>
          <listPosition>13</listPosition>
          <doi>10.1038/nrendo.2012.140</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477456</mtid>
          <link>/api/reference/40477456</link>
          <label>14. Zinman 2015: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes., N. Engl. J. Med., 373, p. 2117, DOI: 10.1056/NEJMoa1504720</label>
          <listPosition>14</listPosition>
          <doi>10.1056/NEJMoa1504720</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477457</mtid>
          <link>/api/reference/40477457</link>
          <label>15. Neal 2017: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes., N. Engl. J. Med., 377, p. 644, DOI: 10.1056/NEJMoa1611925</label>
          <listPosition>15</listPosition>
          <doi>10.1056/NEJMoa1611925</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477458</mtid>
          <link>/api/reference/40477458</link>
          <label>16. Wiviott 2019: Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes., N. Engl. J. Med., 380, p. 347, DOI: 10.1056/NEJMoa1812389</label>
          <listPosition>16</listPosition>
          <doi>10.1056/NEJMoa1812389</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477459</mtid>
          <link>/api/reference/40477459</link>
          <label>17. Marso 2016: Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes., N. Engl. J. Med., 375, p. 311, DOI: 10.1056/NEJMoa1603827</label>
          <listPosition>17</listPosition>
          <doi>10.1056/NEJMoa1603827</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477460</mtid>
          <link>/api/reference/40477460</link>
          <label>18. Marso 2016: Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes., N. Engl. J. Med., 375, p. 1834, DOI: 10.1056/NEJMoa1607141</label>
          <listPosition>18</listPosition>
          <doi>10.1056/NEJMoa1607141</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477461</mtid>
          <link>/api/reference/40477461</link>
          <label>19. Gerstein 2019: Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial., Lancet, 394, p. 121, DOI: 10.1016/S0140-6736(19)31149-3</label>
          <listPosition>19</listPosition>
          <doi>10.1016/S0140-6736(19)31149-3</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477462</mtid>
          <link>/api/reference/40477462</link>
          <label>20. Hernandez 2018: Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial., Lancet, 392, p. 1519, DOI: 10.1016/S0140-6736(18)32261-X</label>
          <listPosition>20</listPosition>
          <doi>10.1016/S0140-6736(18)32261-X</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477463</mtid>
          <link>/api/reference/40477463</link>
          <label>21. Cannon 2020: Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes., N. Engl. J. Med., 383, p. 1425, DOI: 10.1056/NEJMoa2004967</label>
          <listPosition>21</listPosition>
          <doi>10.1056/NEJMoa2004967</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477464</mtid>
          <link>/api/reference/40477464</link>
          <label>22. Cosentino 2020: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD., Eur. Heart J., 41, p. 255, DOI: 10.1093/eurheartj/ehz486</label>
          <listPosition>22</listPosition>
          <doi>10.1093/eurheartj/ehz486</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477465</mtid>
          <link>/api/reference/40477465</link>
          <label>23. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020). KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int., 98, S1–S115., DOI: 10.1016/j.kint.2020.06.019</label>
          <listPosition>23</listPosition>
          <doi>10.1016/j.kint.2020.06.019</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477466</mtid>
          <link>/api/reference/40477466</link>
          <label>24. American Diabetes Association Professional Practice Committee, Draznin, B., Aroda, V.R., Bakris, G., Benson, G., Brown, F.M., Freeman, R., Green, J., Huang, E., and Isaacs, D. (2022). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care, 45, S125–S143., DOI: 10.2337/dc22-S009</label>
          <listPosition>24</listPosition>
          <doi>10.2337/dc22-S009</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477467</mtid>
          <link>/api/reference/40477467</link>
          <label>25. McDonagh 2021: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure., Eur. Heart J., 42, p. 3599, DOI: 10.1093/eurheartj/ehab368</label>
          <listPosition>25</listPosition>
          <doi>10.1093/eurheartj/ehab368</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477468</mtid>
          <link>/api/reference/40477468</link>
          <label>26. Heidenreich 2022: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines., Circulation, 145, p. e895</label>
          <listPosition>26</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477469</mtid>
          <link>/api/reference/40477469</link>
          <label>27. Heerspink 2017: Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE)., Diabetes Obes. Metab., 19, p. 1147, DOI: 10.1111/dom.12925</label>
          <listPosition>27</listPosition>
          <doi>10.1111/dom.12925</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477470</mtid>
          <link>/api/reference/40477470</link>
          <label>28. Jax 2017: A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes., Cardiovasc. Diabetol., 16, p. 13, DOI: 10.1186/s12933-016-0493-3</label>
          <listPosition>28</listPosition>
          <doi>10.1186/s12933-016-0493-3</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477471</mtid>
          <link>/api/reference/40477471</link>
          <label>29. Braunwald 2022: Gliflozins in the Management of Cardiovascular Disease., N. Engl. J. Med., 386, p. 2024, DOI: 10.1056/NEJMra2115011</label>
          <listPosition>29</listPosition>
          <doi>10.1056/NEJMra2115011</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477472</mtid>
          <link>/api/reference/40477472</link>
          <label>30. Verma 2018: SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review., Diabetologia, 61, p. 2108, DOI: 10.1007/s00125-018-4670-7</label>
          <listPosition>30</listPosition>
          <doi>10.1007/s00125-018-4670-7</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477473</mtid>
          <link>/api/reference/40477473</link>
          <label>31. Salvador 2021: The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review., Front. Pharmacol., 12, p. 751214, DOI: 10.3389/fphar.2021.751214</label>
          <listPosition>31</listPosition>
          <doi>10.3389/fphar.2021.751214</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477474</mtid>
          <link>/api/reference/40477474</link>
          <label>32. Kolesnik, E., Scherr, D., Rohrer, U., Benedikt, M., Manninger, M., Sourij, H., and von Lewinski, D. (2022). SGLT2 Inhibitors and Their Antiarrhythmic Properties. Int. J. Mol. Sci., 23., DOI: 10.3390/ijms23031678</label>
          <listPosition>32</listPosition>
          <doi>10.3390/ijms23031678</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477475</mtid>
          <link>/api/reference/40477475</link>
          <label>33. Panda 2023: Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome., Endocr. Metab. Immune. Disord. Drug Targets, 23, p. 179, DOI: 10.2174/1871530322666220531123116</label>
          <listPosition>33</listPosition>
          <doi>10.2174/1871530322666220531123116</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477476</mtid>
          <link>/api/reference/40477476</link>
          <label>34. Maier 2012: Cardiomyocyte-specific IkappaB kinase (IKK)/NF-kappaB activation induces reversible inflammatory cardiomyopathy and heart failure., Proc. Natl. Acad. Sci. USA, 109, p. 11794, DOI: 10.1073/pnas.1116584109</label>
          <listPosition>34</listPosition>
          <doi>10.1073/pnas.1116584109</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477477</mtid>
          <link>/api/reference/40477477</link>
          <label>35. Frieler 2015: Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling., Circulation, 131, p. 1019, DOI: 10.1161/CIRCULATIONAHA.114.008788</label>
          <listPosition>35</listPosition>
          <doi>10.1161/CIRCULATIONAHA.114.008788</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477478</mtid>
          <link>/api/reference/40477478</link>
          <label>36. Abdollahi 2022: Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-kappaB activation in human endothelial cells and differentiated macrophages., Eur. J. Pharmacol., 918, p. 174715, DOI: 10.1016/j.ejphar.2021.174715</label>
          <listPosition>36</listPosition>
          <doi>10.1016/j.ejphar.2021.174715</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477479</mtid>
          <link>/api/reference/40477479</link>
          <label>37. Uthman 2021: Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells., Cardiovasc. Drugs Ther., 35, p. 1083, DOI: 10.1007/s10557-020-07083-w</label>
          <listPosition>37</listPosition>
          <doi>10.1007/s10557-020-07083-w</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477480</mtid>
          <link>/api/reference/40477480</link>
          <label>38. Lee 2021: Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-kappaB, MKK7/JNK, and JAK2/STAT1 Signalling Pathways., J. Immunol. Res., 2021, p. 9944880, DOI: 10.1155/2021/9944880</label>
          <listPosition>38</listPosition>
          <doi>10.1155/2021/9944880</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477481</mtid>
          <link>/api/reference/40477481</link>
          <label>39. Sun 2020: Empagliflozin Ameliorates Obesity-Related Cardiac Dysfunction by Regulating Sestrin2-Mediated AMPK-mTOR Signaling and Redox Homeostasis in High-Fat Diet-Induced Obese Mice., Diabetes, 69, p. 1292, DOI: 10.2337/db19-0991</label>
          <listPosition>39</listPosition>
          <doi>10.2337/db19-0991</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477482</mtid>
          <link>/api/reference/40477482</link>
          <label>40. Faridvand 2022: Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation., Clin. Exp. Pharmacol. Physiol., 49, p. 643, DOI: 10.1111/1440-1681.13638</label>
          <listPosition>40</listPosition>
          <doi>10.1111/1440-1681.13638</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477483</mtid>
          <link>/api/reference/40477483</link>
          <label>41. Feijoo-Bandin, S., Aragon-Herrera, A., Otero-Santiago, M., Anido-Varela, L., Morana-Fernandez, S., Tarazon, E., Rosello-Lleti, E., Portoles, M., Gualillo, O., and Gonzalez-Juanatey, J.R. (2022). Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models. Int. J. Mol. Sci., 23., DOI: 10.3390/ijms23105634</label>
          <listPosition>41</listPosition>
          <doi>10.3390/ijms23105634</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477484</mtid>
          <link>/api/reference/40477484</link>
          <label>42. Li 2023: Canagliflozin inhibits inflammasome activation in diabetic endothelial cells—Revealing a novel calcium-dependent anti-inflammatory effect of canagliflozin on human diabetic endothelial cells., Biomed. Pharmacother., 159, p. 114228, DOI: 10.1016/j.biopha.2023.114228</label>
          <listPosition>42</listPosition>
          <doi>10.1016/j.biopha.2023.114228</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477485</mtid>
          <link>/api/reference/40477485</link>
          <label>43. Nakatsu, Y., Kokubo, H., Bumdelger, B., Yoshizumi, M., Yamamotoya, T., Matsunaga, Y., Ueda, K., Inoue, Y., Inoue, M.K., and Fujishiro, M. (2017). The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice. Int. J. Mol. Sci., 18., DOI: 10.3390/ijms18081704</label>
          <listPosition>43</listPosition>
          <doi>10.3390/ijms18081704</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477486</mtid>
          <link>/api/reference/40477486</link>
          <label>44. Leng 2016: The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE(-/-) Mice., Mediat. Inflamm., 2016, p. 6305735, DOI: 10.1155/2016/6305735</label>
          <listPosition>44</listPosition>
          <doi>10.1155/2016/6305735</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477487</mtid>
          <link>/api/reference/40477487</link>
          <label>45. Ye 2017: SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor., Cardiovasc. Drugs Ther., 31, p. 119, DOI: 10.1007/s10557-017-6725-2</label>
          <listPosition>45</listPosition>
          <doi>10.1007/s10557-017-6725-2</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477488</mtid>
          <link>/api/reference/40477488</link>
          <label>46. Hodrea, J., Saeed, A., Molnar, A., Fintha, A., Barczi, A., Wagner, L.J., Szabo, A.J., Fekete, A., and Balogh, D.B. (2022). SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. PLoS ONE, 17., DOI: 10.1371/journal.pone.0263285</label>
          <listPosition>46</listPosition>
          <doi>10.1371/journal.pone.0263285</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477489</mtid>
          <link>/api/reference/40477489</link>
          <label>47. Penna 2020: Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols., Br. J. Pharmacol., 177, p. 5312, DOI: 10.1111/bph.14993</label>
          <listPosition>47</listPosition>
          <doi>10.1111/bph.14993</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477490</mtid>
          <link>/api/reference/40477490</link>
          <label>48. Yu 2021: Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy., Front. Cardiovasc. Med., 8, p. 768214, DOI: 10.3389/fcvm.2021.768214</label>
          <listPosition>48</listPosition>
          <doi>10.3389/fcvm.2021.768214</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477491</mtid>
          <link>/api/reference/40477491</link>
          <label>49. Hu, J., Xu, J., Tan, X., Li, D., Yao, D., Xu, B., and Lei, Y. (2023). Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation. Naunyn. Schmiedebergs Arch. Pharmacol., DOI: 10.1007/s00210-023-02409-5</label>
          <listPosition>49</listPosition>
          <doi>10.1007/s00210-023-02409-5</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477492</mtid>
          <link>/api/reference/40477492</link>
          <label>50. Chen 2023: Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2., Circulation, 147, p. 276, DOI: 10.1161/CIRCULATIONAHA.122.061688</label>
          <listPosition>50</listPosition>
          <doi>10.1161/CIRCULATIONAHA.122.061688</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477493</mtid>
          <link>/api/reference/40477493</link>
          <label>51. Hattori 2018: Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance., Diabetol. Metab. Syndr., 10, p. 93, DOI: 10.1186/s13098-018-0395-5</label>
          <listPosition>51</listPosition>
          <doi>10.1186/s13098-018-0395-5</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477494</mtid>
          <link>/api/reference/40477494</link>
          <label>52. Sezai 2019: Canagliflozin for Japanese patients with chronic heart failure and type II diabetes., Cardiovasc. Diabetol., 18, p. 76, DOI: 10.1186/s12933-019-0877-2</label>
          <listPosition>52</listPosition>
          <doi>10.1186/s12933-019-0877-2</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477495</mtid>
          <link>/api/reference/40477495</link>
          <label>53. Shigiyama 2017: Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study., Cardiovasc. Diabetol., 16, p. 84, DOI: 10.1186/s12933-017-0564-0</label>
          <listPosition>53</listPosition>
          <doi>10.1186/s12933-017-0564-0</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477496</mtid>
          <link>/api/reference/40477496</link>
          <label>54. Tanaka 2019: Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial., Diabetes Care, 42, p. e159, DOI: 10.2337/dc19-1177</label>
          <listPosition>54</listPosition>
          <doi>10.2337/dc19-1177</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477497</mtid>
          <link>/api/reference/40477497</link>
          <label>55. Kanbay 2022: Effect of sodium-glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: A systematic review and meta-analysis., Int. Urol. Nephrol., 54, p. 827, DOI: 10.1007/s11255-021-02943-2</label>
          <listPosition>55</listPosition>
          <doi>10.1007/s11255-021-02943-2</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477498</mtid>
          <link>/api/reference/40477498</link>
          <label>56. Ghanim 2020: Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis., J. Clin. Endocrinol. Metab., 105, p. e1056, DOI: 10.1210/clinem/dgaa057</label>
          <listPosition>56</listPosition>
          <doi>10.1210/clinem/dgaa057</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477499</mtid>
          <link>/api/reference/40477499</link>
          <label>57. Ma 2020: Liraglutide reduces hyperglycemia-induced cardiomyocyte death through activating glucagon-like peptide 1 receptor and targeting AMPK pathway., J. Recept. Signal Transduct. Res., 40, p. 133, DOI: 10.1080/10799893.2020.1719517</label>
          <listPosition>57</listPosition>
          <doi>10.1080/10799893.2020.1719517</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477500</mtid>
          <link>/api/reference/40477500</link>
          <label>58. Fu 2020: Exenatide inhibits NF-kappaB and attenuates ER stress in diabetic cardiomyocyte models., Aging, 12, p. 8640, DOI: 10.18632/aging.103181</label>
          <listPosition>58</listPosition>
          <doi>10.18632/aging.103181</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477501</mtid>
          <link>/api/reference/40477501</link>
          <label>59. Hattori 2010: A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells., Diabetologia, 53, p. 2256, DOI: 10.1007/s00125-010-1831-8</label>
          <listPosition>59</listPosition>
          <doi>10.1007/s00125-010-1831-8</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477502</mtid>
          <link>/api/reference/40477502</link>
          <label>60. Dai 2013: Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation., Cardiovasc. Drugs Ther., 27, p. 371, DOI: 10.1007/s10557-013-6463-z</label>
          <listPosition>60</listPosition>
          <doi>10.1007/s10557-013-6463-z</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477503</mtid>
          <link>/api/reference/40477503</link>
          <label>61. Krasner, N.M., Ido, Y., Ruderman, N.B., and Cacicedo, J.M. (2014). Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS ONE, 9., DOI: 10.1371/journal.pone.0097554</label>
          <listPosition>61</listPosition>
          <doi>10.1371/journal.pone.0097554</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477504</mtid>
          <link>/api/reference/40477504</link>
          <label>62. Luo 2019: Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation., Arch. Biochem. Biophys., 671, p. 203, DOI: 10.1016/j.abb.2019.07.008</label>
          <listPosition>62</listPosition>
          <doi>10.1016/j.abb.2019.07.008</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477505</mtid>
          <link>/api/reference/40477505</link>
          <label>63. Trang, N.N., Chung, C.C., Lee, T.W., Cheng, W.L., Kao, Y.H., Huang, S.Y., Lee, T.I., and Chen, Y.J. (2021). Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats. Int. J. Mol. Sci., 22., DOI: 10.3390/ijms22031177</label>
          <listPosition>63</listPosition>
          <doi>10.3390/ijms22031177</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477506</mtid>
          <link>/api/reference/40477506</link>
          <label>64. Baylan 2022: Liraglutide treatment attenuates inflammation markers in the cardiac, cerebral and renal microvasculature in streptozotocin-induced diabetic rats., Eur. J. Clin. Investig., 52, p. e13807, DOI: 10.1111/eci.13807</label>
          <listPosition>64</listPosition>
          <doi>10.1111/eci.13807</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477507</mtid>
          <link>/api/reference/40477507</link>
          <label>65. Navabi 2021: Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model., Life Sci., 276, p. 119374, DOI: 10.1016/j.lfs.2021.119374</label>
          <listPosition>65</listPosition>
          <doi>10.1016/j.lfs.2021.119374</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477508</mtid>
          <link>/api/reference/40477508</link>
          <label>66. Wei 2019: Exendin-4 Protects against Hyperglycemia-Induced Cardiomyocyte Pyroptosis via the AMPK-TXNIP Pathway., J. Diabetes Res., 2019, p. 8905917, DOI: 10.1155/2019/8905917</label>
          <listPosition>66</listPosition>
          <doi>10.1155/2019/8905917</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477509</mtid>
          <link>/api/reference/40477509</link>
          <label>67. Zhang 2021: Liraglutide ameliorates myocardial damage in experimental diabetic rats by inhibiting pyroptosis via Sirt1/AMPK signaling., Iran. J. Basic Med. Sci., 24, p. 1358</label>
          <listPosition>67</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477510</mtid>
          <link>/api/reference/40477510</link>
          <label>68. Koshibu 2019: Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms., Am. J. Physiol. Endocrinol. Metab., 316, p. E895, DOI: 10.1152/ajpendo.00511.2018</label>
          <listPosition>68</listPosition>
          <doi>10.1152/ajpendo.00511.2018</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477511</mtid>
          <link>/api/reference/40477511</link>
          <label>69. Rakipovski 2018: The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(-/-) and LDLr(-/-) Mice by a Mechanism That Includes Inflammatory Pathways., JACC Basic Transl. Sci., 3, p. 844, DOI: 10.1016/j.jacbts.2018.09.004</label>
          <listPosition>69</listPosition>
          <doi>10.1016/j.jacbts.2018.09.004</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477512</mtid>
          <link>/api/reference/40477512</link>
          <label>70. Gaspari 2016: Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis., Diab. Vasc. Dis. Res., 13, p. 56, DOI: 10.1177/1479164115605000</label>
          <listPosition>70</listPosition>
          <doi>10.1177/1479164115605000</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477513</mtid>
          <link>/api/reference/40477513</link>
          <label>71. Eid 2021: Exendin-4 Protects Against Myocardial Ischemia-Reperfusion Injury by Upregulation of SIRT1 and SIRT3 and Activation of AMPK., J. Cardiovasc. Transl. Res., 14, p. 619, DOI: 10.1007/s12265-020-09984-5</label>
          <listPosition>71</listPosition>
          <doi>10.1007/s12265-020-09984-5</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477514</mtid>
          <link>/api/reference/40477514</link>
          <label>72. Ma 2016: Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor/AMPKalpha signalling pathway., Br. J. Pharmacol., 173, p. 1502, DOI: 10.1111/bph.13449</label>
          <listPosition>72</listPosition>
          <doi>10.1111/bph.13449</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477515</mtid>
          <link>/api/reference/40477515</link>
          <label>73. Zhou 2015: Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation., Biochem. Biophys. Res. Commun., 468, p. 394, DOI: 10.1016/j.bbrc.2015.09.179</label>
          <listPosition>73</listPosition>
          <doi>10.1016/j.bbrc.2015.09.179</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477516</mtid>
          <link>/api/reference/40477516</link>
          <label>74. Holman 2017: Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes., N. Engl. J. Med., 377, p. 1228, DOI: 10.1056/NEJMoa1612917</label>
          <listPosition>74</listPosition>
          <doi>10.1056/NEJMoa1612917</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477517</mtid>
          <link>/api/reference/40477517</link>
          <label>75. Jensen 2021: Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [(64)Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial., Front. Endocrinol., 12, p. 790405, DOI: 10.3389/fendo.2021.790405</label>
          <listPosition>75</listPosition>
          <doi>10.3389/fendo.2021.790405</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477518</mtid>
          <link>/api/reference/40477518</link>
          <label>76. Nauck 2017: Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors., Circulation, 136, p. 849, DOI: 10.1161/CIRCULATIONAHA.117.028136</label>
          <listPosition>76</listPosition>
          <doi>10.1161/CIRCULATIONAHA.117.028136</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477519</mtid>
          <link>/api/reference/40477519</link>
          <label>77. Daousi 2013: Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?., Regul. Pept., 183, p. 54, DOI: 10.1016/j.regpep.2013.03.004</label>
          <listPosition>77</listPosition>
          <doi>10.1016/j.regpep.2013.03.004</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477520</mtid>
          <link>/api/reference/40477520</link>
          <label>78. Lee 2016: Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control., Mediat. Inflamm., 2016, p. 3094642, DOI: 10.1155/2016/3094642</label>
          <listPosition>78</listPosition>
          <doi>10.1155/2016/3094642</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477521</mtid>
          <link>/api/reference/40477521</link>
          <label>79. Meng 2020: The dipeptidyl peptidase (DPP)-4 inhibitor trelagliptin inhibits IL-1beta-induced endothelial inflammation and monocytes attachment., Int. Immunopharmacol., 89, p. 106996, DOI: 10.1016/j.intimp.2020.106996</label>
          <listPosition>79</listPosition>
          <doi>10.1016/j.intimp.2020.106996</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477522</mtid>
          <link>/api/reference/40477522</link>
          <label>80. Wicinski, M., Gorski, K., Wodkiewicz, E., Walczak, M., Nowaczewska, M., and Malinowski, B. (2020). Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis. Int. J. Mol. Sci., 21., DOI: 10.3390/ijms21072275</label>
          <listPosition>80</listPosition>
          <doi>10.3390/ijms21072275</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477523</mtid>
          <link>/api/reference/40477523</link>
          <label>81. Lee 2016: Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate., Metabolism, 65, p. 89, DOI: 10.1016/j.metabol.2015.10.002</label>
          <listPosition>81</listPosition>
          <doi>10.1016/j.metabol.2015.10.002</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477524</mtid>
          <link>/api/reference/40477524</link>
          <label>82. Qi 2019: Vildagliptin inhibits high free fatty acid (FFA)-induced NLRP3 inflammasome activation in endothelial cells., Artif. Cells Nanomed. Biotechnol., 47, p. 1067, DOI: 10.1080/21691401.2019.1578783</label>
          <listPosition>82</listPosition>
          <doi>10.1080/21691401.2019.1578783</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477525</mtid>
          <link>/api/reference/40477525</link>
          <label>83. Ferreira 2010: Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat)., Mediat. Inflamm., 2010, p. 592760, DOI: 10.1155/2010/592760</label>
          <listPosition>83</listPosition>
          <doi>10.1155/2010/592760</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477526</mtid>
          <link>/api/reference/40477526</link>
          <label>84. Tanajak 2017: Comparisons of cardioprotective efficacy between fibroblast growth factor 21 and dipeptidyl peptidase-4 inhibitor in prediabetic rats., Cardiovasc. Ther., 35, p. e12263, DOI: 10.1111/1755-5922.12263</label>
          <listPosition>84</listPosition>
          <doi>10.1111/1755-5922.12263</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477527</mtid>
          <link>/api/reference/40477527</link>
          <label>85. Aroor 2017: Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice., Cardiovasc. Diabetol., 16, p. 61, DOI: 10.1186/s12933-017-0544-4</label>
          <listPosition>85</listPosition>
          <doi>10.1186/s12933-017-0544-4</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477528</mtid>
          <link>/api/reference/40477528</link>
          <label>86. Hasan 2016: Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats., Drug Des. Devel. Ther., 10, p. 2095, DOI: 10.2147/DDDT.S109287</label>
          <listPosition>86</listPosition>
          <doi>10.2147/DDDT.S109287</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477529</mtid>
          <link>/api/reference/40477529</link>
          <label>87. Birnbaum 2019: DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome., Basic Res. Cardiol., 114, p. 35, DOI: 10.1007/s00395-019-0743-0</label>
          <listPosition>87</listPosition>
          <doi>10.1007/s00395-019-0743-0</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477530</mtid>
          <link>/api/reference/40477530</link>
          <label>88. Shah 2011: Chronic DPP-4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis., Circulation, 124, p. 2338, DOI: 10.1161/CIRCULATIONAHA.111.041418</label>
          <listPosition>88</listPosition>
          <doi>10.1161/CIRCULATIONAHA.111.041418</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477531</mtid>
          <link>/api/reference/40477531</link>
          <label>89. Brown 2017: Dipeptidyl Peptidase-4 Inhibition With Saxagliptin Ameliorates Angiotensin II-Induced Cardiac Diastolic Dysfunction in Male Mice., Endocrinology, 158, p. 3592, DOI: 10.1210/en.2017-00416</label>
          <listPosition>89</listPosition>
          <doi>10.1210/en.2017-00416</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477532</mtid>
          <link>/api/reference/40477532</link>
          <label>90. Younis 2017: The addition of vildagliptin to metformin prevents the elevation of interleukin 1ss in patients with type 2 diabetes and coronary artery disease: A prospective, randomized, open-label study., Cardiovasc. Diabetol., 16, p. 69, DOI: 10.1186/s12933-017-0551-5</label>
          <listPosition>90</listPosition>
          <doi>10.1186/s12933-017-0551-5</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477533</mtid>
          <link>/api/reference/40477533</link>
          <label>91. Sun 2020: Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients., Med. Sci. Monit., 26, p. e921891</label>
          <listPosition>91</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477534</mtid>
          <link>/api/reference/40477534</link>
          <label>92. Teragawa 2020: Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial., Diabetes Metab. Syndr. Obes., 13, p. 4993, DOI: 10.2147/DMSO.S282968</label>
          <listPosition>92</listPosition>
          <doi>10.2147/DMSO.S282968</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477535</mtid>
          <link>/api/reference/40477535</link>
          <label>93. Evans 2002: Oxidative stress and stress-activated signaling pathways: A unifying hypothesis of type 2 diabetes., Endocr. Rev., 23, p. 599, DOI: 10.1210/er.2001-0039</label>
          <listPosition>93</listPosition>
          <doi>10.1210/er.2001-0039</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477536</mtid>
          <link>/api/reference/40477536</link>
          <label>94. Liu 2014: Diabetic cardiomyopathy and its mechanisms: Role of oxidative stress and damage., J. Diabetes Investig., 5, p. 623, DOI: 10.1111/jdi.12250</label>
          <listPosition>94</listPosition>
          <doi>10.1111/jdi.12250</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477537</mtid>
          <link>/api/reference/40477537</link>
          <label>95. Cessario 2021: Empagliflozin, alone or in combination with liraglutide, limits cell death in vitro: Role of oxidative stress and nitric oxide., Pharmacol. Rep., 73, p. 858, DOI: 10.1007/s43440-021-00224-4</label>
          <listPosition>95</listPosition>
          <doi>10.1007/s43440-021-00224-4</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477538</mtid>
          <link>/api/reference/40477538</link>
          <label>96. Bugga 2022: Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress., Life Sci., 307, p. 120862, DOI: 10.1016/j.lfs.2022.120862</label>
          <listPosition>96</listPosition>
          <doi>10.1016/j.lfs.2022.120862</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477539</mtid>
          <link>/api/reference/40477539</link>
          <label>97. Wang 2022: Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function., Oxid. Med. Cell. Longev., 2022, p. 1122494</label>
          <listPosition>97</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477540</mtid>
          <link>/api/reference/40477540</link>
          <label>98. Uthman 2019: Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor alpha-Stimulated Human Coronary Arterial Endothelial Cells., Cell. Physiol. Biochem., 53, p. 865, DOI: 10.33594/000000178</label>
          <listPosition>98</listPosition>
          <doi>10.33594/000000178</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477541</mtid>
          <link>/api/reference/40477541</link>
          <label>99. Uthman 2022: Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na(+)](c)/ROS-pathway in human endothelial cells., Biomed. Pharmacother., 146, p. 112515, DOI: 10.1016/j.biopha.2021.112515</label>
          <listPosition>99</listPosition>
          <doi>10.1016/j.biopha.2021.112515</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477542</mtid>
          <link>/api/reference/40477542</link>
          <label>100. Li 2019: SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart., Cardiovasc. Diabetol., 18, p. 15, DOI: 10.1186/s12933-019-0816-2</label>
          <listPosition>100</listPosition>
          <doi>10.1186/s12933-019-0816-2</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477543</mtid>
          <link>/api/reference/40477543</link>
          <label>101. Tian 2021: Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPKalpha/TGF-beta/Smad signalling in type 2 diabetic rats., J. Cell. Mol. Med., 25, p. 7642, DOI: 10.1111/jcmm.16601</label>
          <listPosition>101</listPosition>
          <doi>10.1111/jcmm.16601</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477544</mtid>
          <link>/api/reference/40477544</link>
          <label>102. Croteau 2021: Effects of Sodium-Glucose Linked Transporter 2 Inhibition With Ertugliflozin on Mitochondrial Function, Energetics, and Metabolic Gene Expression in the Presence and Absence of Diabetes Mellitus in Mice., J. Am. Heart Assoc., 10, p. e019995, DOI: 10.1161/JAHA.120.019995</label>
          <listPosition>102</listPosition>
          <doi>10.1161/JAHA.120.019995</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477545</mtid>
          <link>/api/reference/40477545</link>
          <label>103. Rahadian 2020: Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice., J. Atheroscler. Thromb., 27, p. 1141, DOI: 10.5551/jat.52100</label>
          <listPosition>103</listPosition>
          <doi>10.5551/jat.52100</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477546</mtid>
          <link>/api/reference/40477546</link>
          <label>104. Li 2016: Influence of Dapagliflozin on Glycemic Variations in Patients with Newly Diagnosed Type 2 Diabetes Mellitus., J. Diabetes Res., 2016, p. 5347262, DOI: 10.1155/2016/5347262</label>
          <listPosition>104</listPosition>
          <doi>10.1155/2016/5347262</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477547</mtid>
          <link>/api/reference/40477547</link>
          <label>105. Pignatelli, P., Baratta, F., Buzzetti, R., D’Amico, A., Castellani, V., Bartimoccia, S., Siena, A., D’Onofrio, L., Maddaloni, E., and Pingitore, A. (2022). The Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study. Antioxidants, 11., DOI: 10.3390/antiox11101878</label>
          <listPosition>105</listPosition>
          <doi>10.3390/antiox11101878</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477548</mtid>
          <link>/api/reference/40477548</link>
          <label>106. Zhao 2017: Attenuation of High Glucose-Induced Rat Cardiomyocyte Apoptosis by Exendin-4 via Intervention of HO-1/Nrf-2 and the PI3K/AKT Signaling Pathway., Chin. J. Physiol., 60, p. 89, DOI: 10.4077/CJP.2017.BAF434</label>
          <listPosition>106</listPosition>
          <doi>10.4077/CJP.2017.BAF434</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477549</mtid>
          <link>/api/reference/40477549</link>
          <label>107. Wu 2018: Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARalpha pathway., Aging Cell., 17, p. e12763, DOI: 10.1111/acel.12763</label>
          <listPosition>107</listPosition>
          <doi>10.1111/acel.12763</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477550</mtid>
          <link>/api/reference/40477550</link>
          <label>108. Nuamnaichati 2020: Stimulation of GLP-1 Receptor Inhibits Methylglyoxal-Induced Mitochondrial Dysfunctions in H9c2 Cardiomyoblasts: Potential Role of Epac/PI3K/Akt Pathway., Front. Pharmacol., 11, p. 805, DOI: 10.3389/fphar.2020.00805</label>
          <listPosition>108</listPosition>
          <doi>10.3389/fphar.2020.00805</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477551</mtid>
          <link>/api/reference/40477551</link>
          <label>109. Qian 2020: A novel oral glucagon-like peptide 1 receptor agonist protects against diabetic cardiomyopathy via alleviating cardiac lipotoxicity induced mitochondria dysfunction., Biochem. Pharmacol., 182, p. 114209, DOI: 10.1016/j.bcp.2020.114209</label>
          <listPosition>109</listPosition>
          <doi>10.1016/j.bcp.2020.114209</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477552</mtid>
          <link>/api/reference/40477552</link>
          <label>110. Zhang 2020: GLP-1 receptor agonist liraglutide protects cardiomyocytes from IL-1beta-induced metabolic disturbance and mitochondrial dysfunction., Chem. Biol. Interact., 332, p. 109252, DOI: 10.1016/j.cbi.2020.109252</label>
          <listPosition>110</listPosition>
          <doi>10.1016/j.cbi.2020.109252</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477553</mtid>
          <link>/api/reference/40477553</link>
          <label>111. Monji 2013: Glucagon-like peptide-1 receptor activation reverses cardiac remodeling via normalizing cardiac steatosis and oxidative stress in type 2 diabetes., Am. J. Physiol. Heart Circ. Physiol., 305, p. H295, DOI: 10.1152/ajpheart.00990.2012</label>
          <listPosition>111</listPosition>
          <doi>10.1152/ajpheart.00990.2012</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477554</mtid>
          <link>/api/reference/40477554</link>
          <label>112. Ding 2019: Exenatide Protects Against Cardiac Dysfunction by Attenuating Oxidative Stress in the Diabetic Mouse Heart., Front. Endocrinol., 10, p. 202, DOI: 10.3389/fendo.2019.00202</label>
          <listPosition>112</listPosition>
          <doi>10.3389/fendo.2019.00202</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477555</mtid>
          <link>/api/reference/40477555</link>
          <label>113. Inoue 2015: GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats., Atherosclerosis, 240, p. 250, DOI: 10.1016/j.atherosclerosis.2015.03.026</label>
          <listPosition>113</listPosition>
          <doi>10.1016/j.atherosclerosis.2015.03.026</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477556</mtid>
          <link>/api/reference/40477556</link>
          <label>114. Li 2019: A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up., J. Diabetes Res., 2019, p. 6423987, DOI: 10.1155/2019/6423987</label>
          <listPosition>114</listPosition>
          <doi>10.1155/2019/6423987</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477557</mtid>
          <link>/api/reference/40477557</link>
          <label>115. Zhang 2020: Saxagliptin protects against hypoxia-induced damage in H9c2 cells., Chem. Biol. Interact., 315, p. 108864, DOI: 10.1016/j.cbi.2019.108864</label>
          <listPosition>115</listPosition>
          <doi>10.1016/j.cbi.2019.108864</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477558</mtid>
          <link>/api/reference/40477558</link>
          <label>116. Lin 2021: Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice., Sci. Rep., 11, p. 17851, DOI: 10.1038/s41598-021-97361-w</label>
          <listPosition>116</listPosition>
          <doi>10.1038/s41598-021-97361-w</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477559</mtid>
          <link>/api/reference/40477559</link>
          <label>117. Apaijai 2013: Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats., Br. J. Pharmacol., 169, p. 1048, DOI: 10.1111/bph.12176</label>
          <listPosition>117</listPosition>
          <doi>10.1111/bph.12176</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477560</mtid>
          <link>/api/reference/40477560</link>
          <label>118. Zhang 2018: Alogliptin prevents diastolic dysfunction and preserves left ventricular mitochondrial function in diabetic rabbits., Cardiovasc. Diabetol., 17, p. 160, DOI: 10.1186/s12933-018-0803-z</label>
          <listPosition>118</listPosition>
          <doi>10.1186/s12933-018-0803-z</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477561</mtid>
          <link>/api/reference/40477561</link>
          <label>119. Zhang 2017: Alogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits., J. Am. Heart Assoc., 6, p. e005945, DOI: 10.1161/JAHA.117.005945</label>
          <listPosition>119</listPosition>
          <doi>10.1161/JAHA.117.005945</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477562</mtid>
          <link>/api/reference/40477562</link>
          <label>120. Nath 2017: A murine model of type 2 diabetes mellitus developed using a combination of high fat diet and multiple low doses of streptozotocin treatment mimics the metabolic characteristics of type 2 diabetes mellitus in humans., J. Pharmacol. Toxicol. Methods, 84, p. 20, DOI: 10.1016/j.vascn.2016.10.007</label>
          <listPosition>120</listPosition>
          <doi>10.1016/j.vascn.2016.10.007</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477563</mtid>
          <link>/api/reference/40477563</link>
          <label>121. Matsui 2011: Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis., Pharmacol. Res., 63, p. 383, DOI: 10.1016/j.phrs.2011.02.003</label>
          <listPosition>121</listPosition>
          <doi>10.1016/j.phrs.2011.02.003</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477564</mtid>
          <link>/api/reference/40477564</link>
          <label>122. Aroor 2013: Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats., Endocrinology, 154, p. 2501, DOI: 10.1210/en.2013-1096</label>
          <listPosition>122</listPosition>
          <doi>10.1210/en.2013-1096</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477565</mtid>
          <link>/api/reference/40477565</link>
          <label>123. De Geest, B., and Mishra, M. (2022). Role of Oxidative Stress in Diabetic Cardiomyopathy. Antioxidants, 11., DOI: 10.3390/antiox11040784</label>
          <listPosition>123</listPosition>
          <doi>10.3390/antiox11040784</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477566</mtid>
          <link>/api/reference/40477566</link>
          <label>124. Fan 2012: Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease., Fibrogenesis Tissue Repair, 5, p. 15, DOI: 10.1186/1755-1536-5-15</label>
          <listPosition>124</listPosition>
          <doi>10.1186/1755-1536-5-15</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477567</mtid>
          <link>/api/reference/40477567</link>
          <label>125. Li 2004: Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: Implications for diabetic renal and vascular disease., FASEB J., 18, p. 176, DOI: 10.1096/fj.02-1117fje</label>
          <listPosition>125</listPosition>
          <doi>10.1096/fj.02-1117fje</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477568</mtid>
          <link>/api/reference/40477568</link>
          <label>126. Peng 2016: AGE-RAGE signal generates a specific NF-kappaB RelA “barcode” that directs collagen I expression., Sci. Rep., 6, p. 18822, DOI: 10.1038/srep18822</label>
          <listPosition>126</listPosition>
          <doi>10.1038/srep18822</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477569</mtid>
          <link>/api/reference/40477569</link>
          <label>127. Tuleta 2021: Fibrosis of the diabetic heart: Clinical significance, molecular mechanisms, and therapeutic opportunities., Adv. Drug Deliv. Rev., 176, p. 113904, DOI: 10.1016/j.addr.2021.113904</label>
          <listPosition>127</listPosition>
          <doi>10.1016/j.addr.2021.113904</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477570</mtid>
          <link>/api/reference/40477570</link>
          <label>128. Kong 2014: The pathogenesis of cardiac fibrosis., Cell. Mol. Life. Sci., 71, p. 549, DOI: 10.1007/s00018-013-1349-6</label>
          <listPosition>128</listPosition>
          <doi>10.1007/s00018-013-1349-6</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477571</mtid>
          <link>/api/reference/40477571</link>
          <label>129. Wong 2014: Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission., Eur. Heart J., 35, p. 657, DOI: 10.1093/eurheartj/eht193</label>
          <listPosition>129</listPosition>
          <doi>10.1093/eurheartj/eht193</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477572</mtid>
          <link>/api/reference/40477572</link>
          <label>130. Kang 2020: Direct Effects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG OUTCOME Results., Can. J. Cardiol., 36, p. 543, DOI: 10.1016/j.cjca.2019.08.033</label>
          <listPosition>130</listPosition>
          <doi>10.1016/j.cjca.2019.08.033</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477573</mtid>
          <link>/api/reference/40477573</link>
          <label>131. Osaka 2022: Luseogliflozin inhibits high glucose-induced TGF-beta2 expression in mouse cardiomyocytes by suppressing NHE-1 activity., J. Int. Med. Res., 50, p. 3000605221097490, DOI: 10.1177/03000605221097490</label>
          <listPosition>131</listPosition>
          <doi>10.1177/03000605221097490</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477574</mtid>
          <link>/api/reference/40477574</link>
          <label>132. Verma 2019: Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial., Circulation, 140, p. 1693, DOI: 10.1161/CIRCULATIONAHA.119.042375</label>
          <listPosition>132</listPosition>
          <doi>10.1161/CIRCULATIONAHA.119.042375</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477575</mtid>
          <link>/api/reference/40477575</link>
          <label>133. Brown 2020: A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: The DAPA-LVH trial., Eur. Heart J., 41, p. 3421, DOI: 10.1093/eurheartj/ehaa419</label>
          <listPosition>133</listPosition>
          <doi>10.1093/eurheartj/ehaa419</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477576</mtid>
          <link>/api/reference/40477576</link>
          <label>134. Wang 2016: Effects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro., Acta Pharmacol. Sin., 37, p. 1349, DOI: 10.1038/aps.2016.72</label>
          <listPosition>134</listPosition>
          <doi>10.1038/aps.2016.72</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477577</mtid>
          <link>/api/reference/40477577</link>
          <label>135. Zhao 2019: Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1., Biomed. Pharmacother., 118, p. 109224, DOI: 10.1016/j.biopha.2019.109224</label>
          <listPosition>135</listPosition>
          <doi>10.1016/j.biopha.2019.109224</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477578</mtid>
          <link>/api/reference/40477578</link>
          <label>136. Yu 2018: Exendin-4 and Liraglutide Attenuate Glucose Toxicity-Induced Cardiac Injury through mTOR/ULK1-Dependent Autophagy., Oxid. Med. Cell. Longev., 2018, p. 5396806, DOI: 10.1155/2018/5396806</label>
          <listPosition>136</listPosition>
          <doi>10.1155/2018/5396806</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477579</mtid>
          <link>/api/reference/40477579</link>
          <label>137. Cai 2022: Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats., Biochem. Biophys. Res. Commun., 629, p. 112, DOI: 10.1016/j.bbrc.2022.09.018</label>
          <listPosition>137</listPosition>
          <doi>10.1016/j.bbrc.2022.09.018</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477580</mtid>
          <link>/api/reference/40477580</link>
          <label>138. Tate 2016: Exendin-4 attenuates adverse cardiac remodelling in streptozocin-induced diabetes via specific actions on infiltrating macrophages., Basic Res. Cardiol., 111, p. 1, DOI: 10.1007/s00395-015-0518-1</label>
          <listPosition>138</listPosition>
          <doi>10.1007/s00395-015-0518-1</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477581</mtid>
          <link>/api/reference/40477581</link>
          <label>139. Younce 2014: Exendin-4 improves cardiac function in mice overexpressing monocyte chemoattractant protein-1 in cardiomyocytes., J. Mol. Cell. Cardiol., 76, p. 172, DOI: 10.1016/j.yjmcc.2014.08.022</label>
          <listPosition>139</listPosition>
          <doi>10.1016/j.yjmcc.2014.08.022</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477582</mtid>
          <link>/api/reference/40477582</link>
          <label>140. Withaar 2021: The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction., Cardiovasc. Res., 117, p. 2108, DOI: 10.1093/cvr/cvaa256</label>
          <listPosition>140</listPosition>
          <doi>10.1093/cvr/cvaa256</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477583</mtid>
          <link>/api/reference/40477583</link>
          <label>141. Picatoste, B., Ramirez, E., Caro-Vadillo, A., Iborra, C., Ares-Carrasco, S., Egido, J., Tunon, J., and Lorenzo, O. (2013). Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms. PLoS ONE, 8., DOI: 10.1371/annotation/df98874f-c1bd-4a13-b474-942fbb956287</label>
          <listPosition>141</listPosition>
          <doi>10.1371/annotation/df98874f-c1bd-4a13-b474-942fbb956287</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477584</mtid>
          <link>/api/reference/40477584</link>
          <label>142. Liu 2015: Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats., J. Pharmacol. Sci., 127, p. 260, DOI: 10.1016/j.jphs.2014.12.007</label>
          <listPosition>142</listPosition>
          <doi>10.1016/j.jphs.2014.12.007</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477585</mtid>
          <link>/api/reference/40477585</link>
          <label>143. Chen 2021: Effects of Sitagliptin on myocardial remodeling and autophagy in diabetic mice and its mechanism., Chin. J. Appl. Physiol., 37, p. 534</label>
          <listPosition>143</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477586</mtid>
          <link>/api/reference/40477586</link>
          <label>144. Lenski 2011: Effects of DPP-4 inhibition on cardiac metabolism and function in mice., J. Mol. Cell. Cardiol., 51, p. 906, DOI: 10.1016/j.yjmcc.2011.08.001</label>
          <listPosition>144</listPosition>
          <doi>10.1016/j.yjmcc.2011.08.001</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477587</mtid>
          <link>/api/reference/40477587</link>
          <label>145. Moon, J.Y., Woo, J.S., Seo, J.W., Lee, A., Kim, D.J., Kim, Y.G., Kim, S.Y., Lee, K.H., Lim, S.J., and Cheng, X.W. (2016). The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes. PLoS ONE, 11., DOI: 10.1371/journal.pone.0150745</label>
          <listPosition>145</listPosition>
          <doi>10.1371/journal.pone.0150745</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477588</mtid>
          <link>/api/reference/40477588</link>
          <label>146. Bostick 2014: Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity., Metabolism, 63, p. 1000, DOI: 10.1016/j.metabol.2014.04.002</label>
          <listPosition>146</listPosition>
          <doi>10.1016/j.metabol.2014.04.002</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477589</mtid>
          <link>/api/reference/40477589</link>
          <label>147. Hong 2017: Dipeptidyl peptidase 4 inhibitor attenuates obesity-induced myocardial fibrosis by inhibiting transforming growth factor-betal and Smad2/3 pathways in high-fat diet-induced obesity rat model., Metabolism, 76, p. 42, DOI: 10.1016/j.metabol.2017.07.007</label>
          <listPosition>147</listPosition>
          <doi>10.1016/j.metabol.2017.07.007</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477590</mtid>
          <link>/api/reference/40477590</link>
          <label>148. Connelly 2013: DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes., Cardiovasc. Ther., 31, p. 259, DOI: 10.1111/1755-5922.12005</label>
          <listPosition>148</listPosition>
          <doi>10.1111/1755-5922.12005</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477591</mtid>
          <link>/api/reference/40477591</link>
          <label>149. Gu 2018: Sitagliptin improves cardiac function after myocardial infarction through activation of autophagy in streptozotocin-induced diabetic mice., Eur. Rev. Med. Pharmacol. Sci., 22, p. 8973</label>
          <listPosition>149</listPosition>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477592</mtid>
          <link>/api/reference/40477592</link>
          <label>150. Nakajima 2019: A dipeptidyl peptidase-IV inhibitor improves diastolic dysfunction in Dahl salt-sensitive rats., J. Mol. Cell. Cardiol., 129, p. 257, DOI: 10.1016/j.yjmcc.2019.03.009</label>
          <listPosition>150</listPosition>
          <doi>10.1016/j.yjmcc.2019.03.009</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477593</mtid>
          <link>/api/reference/40477593</link>
          <label>151. Nikolaou 2022: Cardioprotection by selective SGLT-2 inhibitors in a non-diabetic mouse model of myocardial ischemia/reperfusion injury: A class or a drug effect?., Basic Res. Cardiol., 117, p. 27, DOI: 10.1007/s00395-022-00934-7</label>
          <listPosition>151</listPosition>
          <doi>10.1007/s00395-022-00934-7</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
        <reference>
          <otype>Reference</otype>
          <mtid>40477594</mtid>
          <link>/api/reference/40477594</link>
          <label>152. Chan, J.C.H., and Chan, M.C.Y. (2023). SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?. Medicina, 59., DOI: 10.3390/medicina59020388</label>
          <listPosition>152</listPosition>
          <doi>10.3390/medicina59020388</doi>
          <published>false</published>
          <snippet>true</snippet>
        </reference>
      </references>
      <link>/api/publication/33770031</link>
      <label>Balogh Dora Bianka et al. An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis. (2023) INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 1661-6596 1422-0067 24 9</label><template>&lt;div class=&quot;JournalArticle Publication short-list&quot;&gt; &lt;div class=&quot;authors&quot;&gt; &lt;span class=&quot;author-name&quot; mtid=&quot;10052792&quot;&gt; &lt;a href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10052792&quot; target=&quot;_blank&quot;&gt;Balogh, Dora Bianka&lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; mtid=&quot;10020375&quot;&gt; &lt;a href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10020375&quot; target=&quot;_blank&quot;&gt;Wagner, Laszlo Jozsef&lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; ; &lt;span class=&quot;author-name&quot; mtid=&quot;10011883&quot;&gt; &lt;a href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10011883&quot; target=&quot;_blank&quot;&gt;Fekete, Andrea ✉&lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;author-type&quot;&gt; &lt;/span&gt; &lt;/div &gt;&lt;div class=&quot;title&quot;&gt;&lt;a href=&quot;/gui2/?mode=browse&amp;params=publication;33770031&quot; mtid=&quot;33770031&quot; target=&quot;_blank&quot;&gt;An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis&lt;/a&gt;&lt;/div&gt; &lt;div class=&quot;pub-info&quot;&gt; &lt;span class=&quot;journal-title&quot;&gt;INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES&lt;/span&gt; &lt;span class=&quot;journal-volume&quot;&gt;24&lt;/span&gt; : &lt;span class=&quot;journal-issue&quot;&gt;9&lt;/span&gt; &lt;span class=&quot;page&quot;&gt; Paper: 7789 , 18 p. &lt;/span&gt; &lt;span class=&quot;year&quot;&gt;(2023)&lt;/span&gt; &lt;/div&gt; &lt;div class=&quot;pub-end&quot;&gt;&lt;div class=&quot;identifier-list&quot;&gt; &lt;span class=&quot;identifiers&quot;&gt; &lt;span class=&quot;id identifier oa_GOLD&quot; title=&quot; Gold &quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;10.3390/ijms24097789&quot; target=&quot;_blank&quot; href=&quot;https://doi.org/10.3390/ijms24097789&quot;&gt; DOI &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;000987420600001&quot; target=&quot;_blank&quot; href=&quot;https://www.webofscience.com/wos/woscc/full-record/000987420600001&quot;&gt; WoS &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;85159311837&quot; target=&quot;_blank&quot; href=&quot;http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85159311837&quot;&gt; Scopus &lt;/a&gt; &lt;/span&gt; &lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt; &lt;a style=&quot;color:blue&quot; title=&quot;37175496&quot; target=&quot;_blank&quot; href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=37175496&amp;dopt=Abstract&quot;&gt; PubMed &lt;/a&gt; &lt;/span&gt; &lt;/span&gt; &lt;/div&gt; &lt;div class=&quot;short-pub-prop-list&quot;&gt; &lt;span class=&quot;short-pub-mtid&quot;&gt; Közlemény:33770031 &lt;/span&gt; &lt;span class=&quot;status-holder&quot;&gt;&lt;span class=&quot;status-data status-VALIDATED&quot;&gt; Egyeztetett &lt;/span&gt;&lt;/span&gt; &lt;span class=&quot;pub-core&quot;&gt;Forrás Idéző &lt;/span&gt; &lt;span class=&quot;pub-type&quot;&gt;Folyóiratcikk (Összefoglaló cikk ) &lt;/span&gt; &lt;!-- &amp;&amp; !record.category.scientific --&gt; &lt;span class=&quot;pub-category&quot;&gt;Tudományos&lt;/span&gt; &lt;div class=&quot;publication-citation&quot; style=&quot;margin-left: 0.5cm;&quot;&gt; &lt;span title=&quot;Nyilvános idézőközlemények összesen, említések nélkül&quot; class=&quot;citingPub-count&quot;&gt;Nyilvános idéző összesen: 47&lt;/span&gt; | Független: 47 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 36 | Scopus jelölt:&amp;nbsp;37 | WoS/Scopus jelölt:&amp;nbsp;40 | DOI jelölt:&amp;nbsp;42 &lt;/div&gt; &lt;/div&gt; &lt;/div&gt; &lt;/div&gt;</template><template2>&lt;div class=&quot;JournalArticle Publication long-list&quot;&gt;
&lt;div class=&quot;authors&quot;&gt;
	&lt;img title=&quot;Forrásközlemény&quot; style=&quot;float: left&quot; src=&quot;/frontend/resources/grid/publication-core-icon.png&quot;&gt;
	&lt;img title=&quot;Idézőközlemény&quot; style=&quot;float: left&quot; src=&quot;/frontend/resources/grid/publication-citation-icon.png&quot;&gt;

		&lt;div class=&quot;autype autype0&quot;&gt;				&lt;span class=&quot;author-name&quot; mtid=&quot;10052792&quot;&gt;&lt;a 
																				   href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10052792&quot; target=&quot;_blank&quot;&gt;Balogh Dora Bianka
            (&lt;span class=&quot;authorship-author-name&quot;&gt;Balogh Dóra Bianka&lt;/span&gt;
            &lt;span class=&quot;authorAux-mtmt&quot;&gt; Molekuláris biológia, Szülészet-nőgyógyászat&lt;/span&gt;)
			&lt;/a&gt;
    &lt;/span&gt;
&lt;span class=&quot;author-affil&quot;&gt;&lt;span title=&quot;Semmelweis Egyetem&quot;&gt;SE&lt;/span&gt;/&lt;span title=&quot;Általános Orvostudományi Kar&quot;&gt;AOK&lt;/span&gt;/&lt;span title=&quot;Klinikum&quot;&gt;K&lt;/span&gt;/&lt;span title=&quot;Gyermekgyógyászati Klinika&quot;&gt;GYGYK&lt;/span&gt;/MTA-SE Lendület Diabétesz Kutatócsoport; &lt;span title=&quot;Semmelweis Egyetem&quot;&gt;SE&lt;/span&gt;/&lt;span title=&quot;Általános Orvostudományi Kar&quot;&gt;AOK&lt;/span&gt;/&lt;span title=&quot;Klinikum&quot;&gt;K&lt;/span&gt;/Gyermekgyógyászati Klinika&lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; mtid=&quot;10020375&quot;&gt;&lt;a 
																				   href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10020375&quot; target=&quot;_blank&quot;&gt;Wagner Laszlo Jozsef
            (&lt;span class=&quot;authorship-author-name&quot;&gt;Wágner László József&lt;/span&gt;
            &lt;span class=&quot;authorAux-mtmt&quot;&gt; Transzplantáció&lt;/span&gt;)
			&lt;/a&gt;
    &lt;/span&gt;
&lt;span class=&quot;author-affil&quot;&gt;&lt;span title=&quot;Semmelweis Egyetem&quot;&gt;SE&lt;/span&gt;/&lt;span title=&quot;Általános Orvostudományi Kar&quot;&gt;AOK&lt;/span&gt;/&lt;span title=&quot;Klinikum&quot;&gt;K&lt;/span&gt;/Sebészeti, Transzplantációs és Gasztroenterológiai Klinika&lt;/span&gt;
;&amp;nbsp;&amp;nbsp;&amp;nbsp;
							&lt;span class=&quot;author-name&quot; mtid=&quot;10011883&quot;&gt;&lt;a 
																				   href=&quot;/gui2/?type=authors&amp;mode=browse&amp;sel=10011883&quot; target=&quot;_blank&quot;&gt;Fekete Andrea ✉
            (&lt;span class=&quot;authorship-author-name&quot;&gt;Fekete Andrea&lt;/span&gt;
            &lt;span class=&quot;authorAux-mtmt&quot;&gt; nefrológia, gyermekgyógyászat&lt;/span&gt;)
			&lt;/a&gt;
    &lt;/span&gt;
&lt;span class=&quot;author-affil&quot;&gt;&lt;span title=&quot;Semmelweis Egyetem&quot;&gt;SE&lt;/span&gt;/&lt;span title=&quot;Általános Orvostudományi Kar&quot;&gt;AOK&lt;/span&gt;/&lt;span title=&quot;Klinikum&quot;&gt;K&lt;/span&gt;/&lt;span title=&quot;Gyermekgyógyászati Klinika&quot;&gt;GYGYK&lt;/span&gt;/MTA-SE Lendület Diabétesz Kutatócsoport; &lt;span title=&quot;Semmelweis Egyetem&quot;&gt;SE&lt;/span&gt;/&lt;span title=&quot;Általános Orvostudományi Kar&quot;&gt;AOK&lt;/span&gt;/&lt;span title=&quot;Klinikum&quot;&gt;K&lt;/span&gt;/Gyermekgyógyászati Klinika&lt;/span&gt;

				    &lt;/div&gt;
&lt;/div&gt;
&lt;div class=&quot;title&quot;&gt;&lt;a href=&quot;/gui2/?mode=browse&amp;params=publication;33770031&quot; target=&quot;_blank&quot;&gt;An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis&lt;/a&gt;&lt;/div&gt;    &lt;div&gt;		&lt;span class=&quot;journal-title&quot;&gt;INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES&lt;/span&gt;

        &lt;span class=&quot;journal-issn&quot;&gt;(&lt;a target=&quot;_blank&quot; href=&quot;https://portal.issn.org/resource/ISSN/1661-6596&quot;&gt;1661-6596&lt;/a&gt; &lt;a target=&quot;_blank&quot; href=&quot;https://portal.issn.org/resource/ISSN/1422-0067&quot;&gt;1422-0067&lt;/a&gt;)&lt;/span&gt;:
		&lt;span class=&quot;journal-volume&quot;&gt;24&lt;/span&gt; &lt;span class=&quot;journal-issue&quot;&gt;9&lt;/span&gt;
&lt;span class=&quot;page&quot;&gt;
		Paper 7789.
	 18 p. 
&lt;/span&gt;		 &lt;span class=&quot;year&quot;&gt;(2023)&lt;/span&gt;  
    &lt;/div&gt;
&lt;div class=&quot;pub-footer&quot;&gt;
    

	&lt;span class=&quot;language&quot; xmlns=&quot;http://www.w3.org/1999/html&quot;&gt;Nyelv:
			Angol
		 |  &lt;/span&gt;

	&lt;span class=&quot;identifiers&quot;&gt;
						&lt;span class=&quot;id identifier oa_GOLD&quot; title=&quot;	Gold
&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;10.3390/ijms24097789&quot; target=&quot;_blank&quot; href=&quot;https://doi.org/10.3390/ijms24097789&quot;&gt;
									DOI
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;000987420600001&quot; target=&quot;_blank&quot; href=&quot;https://www.webofscience.com/wos/woscc/full-record/000987420600001&quot;&gt;
									WoS
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;85159311837&quot; target=&quot;_blank&quot; href=&quot;http://www.scopus.com/record/display.url?origin=inward&amp;eid=2-s2.0-85159311837&quot;&gt;
									Scopus
							&lt;/a&gt;
						&lt;/span&gt;
						&lt;span class=&quot;id identifier oa_none&quot; title=&quot;none&quot;&gt;
							
							&lt;a style=&quot;color:blue&quot; title=&quot;37175496&quot; target=&quot;_blank&quot; href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=37175496&amp;dopt=Abstract&quot;&gt;
									PubMed
							&lt;/a&gt;
						&lt;/span&gt;
	&lt;/span&gt;


	&lt;OnlyViewableByAuthor&gt;&lt;div class=&quot;ratings&quot;&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Inorganic Chemistry&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;D1&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Organic Chemistry&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;D1&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Spectroscopy&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;D1&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Computer Science Applications&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;Q1&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;Q1&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Physical and Theoretical Chemistry&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;Q1&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Catalysis&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;Q2&lt;/div&gt;
				&lt;div class=&quot;journal-subject&quot;&gt;Folyóirat szakterülete: Scopus - Molecular Biology&amp;nbsp;&amp;nbsp;&amp;nbsp;SJR indikátor:&amp;nbsp;Q2&lt;/div&gt;
    &lt;/div&gt;&lt;/OnlyViewableByAuthor&gt;


	&lt;div class=&quot;publication-citation&quot; style=&quot;margin-left: 0.5cm;&quot;&gt;
		&lt;span title=&quot;Nyilvános idézőközlemények összesen, említések nélkül&quot; class=&quot;citingPub-count&quot;&gt;Nyilvános idéző összesen: 47&lt;/span&gt;
		| Független: 47
		| Függő: 0
		| Nem jelölt: 0
		| WoS jelölt: 36 
		|  Scopus jelölt:&amp;nbsp;37 
		|  WoS/Scopus jelölt:&amp;nbsp;40 
		|  DOI jelölt:&amp;nbsp;42 
		
	&lt;/div&gt;
    
    
	&lt;div class=&quot;publication-citation&quot;&gt;
		&lt;a target=&quot;_blank&quot; href=&quot;/api/publication?cond=citations.related;eq;33770031&amp;sort=publishedYear,desc&amp;sort=title&quot;&gt;
			Idézett közlemények száma: 8
		&lt;/a&gt;
	&lt;/div&gt;



    &lt;div class=&quot;mtid&quot;&gt;&lt;span class=&quot;long-pub-mtid&quot;&gt;Közlemény: 33770031&lt;/span&gt;
    | &lt;span class=&quot;status-data status-VALIDATED&quot;&gt; 	Egyeztetett
  &lt;/span&gt;
        
	
	
Forrás	 Idéző
	
	
    | &lt;span class=&quot;type-subtype&quot;&gt;Folyóiratcikk
			( Összefoglaló cikk
			
			)
		&lt;/span&gt;
      		| &lt;span class=&quot;pub-category&quot;&gt;Tudományos&lt;/span&gt;
	| &lt;span class=&quot;publication-sourceOfData&quot;&gt;kézi felvitel&lt;/span&gt;
&lt;/div&gt;

&lt;div class=&quot;funder&quot;&gt; (UNKP-22-4-II-SE-2),    (TKP2021-EGA-24),    (TKP2021-EGA-24)   &lt;/div&gt;
&lt;div class=&quot;lastModified&quot;&gt;Utolsó módosítás: 2025.11.18. 10:25 Milánkovics Róbert (PTE ÁOK admin 4)
&lt;/div&gt;




	&lt;pre class=&quot;comment&quot; style=&quot;margin-top: 0; margin-bottom: 0;&quot;&gt;&lt;u&gt;Megjegyzés&lt;/u&gt;: Cited By :12            
            Export Date: 10 December 2024            
            Correspondence Address: Fekete, A.; Pediatric Center, Hungary; email: fekete.andrea@med.semmelweis-univ.hu&lt;/pre&gt;
&lt;/div&gt;&lt;/div&gt;</template2>
    </publication>
  </content>
</myciteResult>
